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Increase in the copy number of ERBB2, a Tyrosine Kinase Receptor (TKR) leads to the overexpression of onco-
gene product and consequently uncontrolled cell proliferation which has been reported in different aggressive 
cancers with mitochondrial malfunctions. Although, amplification of ERBB2 has been reported in different stud-
ies; however, the association between changes in mitochondrial DNA content and the ERBB2 gene copy number 
is poorly understood. The relative mitochondrial DNA content of breast cancer tumor tissues of 70 patients who 
were referred to Imam Khomeini Hospital Complex was determined using quantitative Real-time PCR. Multi-
plex ligation-dependent probe amplification (MLPA) was conducted to evaluate the ERBB2 gene copy number 
variation and finally, two-sample Wilcoxon rank-sum (Mann-Whitney) test was used to investigate the possible 
association between mitochondrial DNA (mtDNA) content and the ERBB2 gene amplification. Seventeen out of 
70 breast cancer tumor tissues were found with ERBB2 gene amplification. Comparison of the mitochondrial 
DNA content of the aforementioned samples with the rest of the cases showed a significant decrease in the mito-
chondrial DNA content of the ERBB2-amplified samples (P=0.01). Our data provided evidence that ERBB2 have 
the potential to have a regulatory role over mitochondrial activity by controlling the mtDNA content. 
 






Breast cancer is the most frequently di-
agnosed type of malignancy in women 
worldwide which accounts for about 29 % of 
all cancer types affecting females. According 
to the WHO estimation, there will be 
246.660 new cases of breast cancer and 
40.450 cases of deaths in the US in 2016 
(Siegel et al., 2016). The incidence rate of 
breast cancer is also rapidly increasing in 
Asia, Middle East and also in Iran (Harirchi 
et al., 2004; Thyagarajan et al., 2013). In the 
recent years, there has been a remarkable 
growth in the whole globe to improve the 
conventional cancer screening outcomes by 
using cancer-related genetic markers. Alt-
hough alteration in genetic and epigenetic in 
genomic DNA encoded oncogenes and tu-
mor suppressor genes have been in the focus 
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of many researchers for many years, howev-
er, changes in mtDNA content has recently 
been a topic for debate to be used as a mo-
lecular biomarker for early detection (Yu, 
2011).  
Mitochondria are semiautonomous, cyto-
plasmic compartments of eukaryotic cells 
that have crucial roles in energy metabolism, 
generating free radicals, calcium homeostasis 
and programmed cell death. They have their 
own DNA called mtDNA which is a circular, 
double-stranded DNA with 16569bp length. 
It encodes 13 subunits of respiratory chain 
complexes, 2 ribosomal RNAs and a set of 
22 transfer RNAs that are needed for synthe-
sis of mitochondrial proteins. There are ten 
to thousands copies of mtDNA in each eu-
karyotic cell. Different tissues and cell types 
have different mtDNA content depending on 
its physiological circumstances and micro-
environment condition (Wang et al., 2006; 
Yu et al., 2007; Shen et al., 2010; Jiang et 
al., 2014). It has been proposed that changes 
in mitochondrial DNA are in association to 
mitochondrial malfunctions suggesting that it 
may contribute to diseases including cancer 
(Bai et al., 2011). Mitochondrial malfunc-
tions can prompt the cells to escape from the 
normal apoptotic pathway and to initiate the 
neoplastic alteration (Wang et al., 2006; Yu 
et al., 2007).  
Changes in the mitochondrial DNA con-
tent trigger retrograde signaling pathway 
which is a crosstalk between mitochondria 
and the nucleus. In the normal cells, gene 
expression needs high energy which is pro-
vided by oxidative phosphorylation supple-
mented by mitochondria. Therefore, changes 
in the mitochondrial DNA content or func-
tion could possibly lead to changes in the 
ATP content which may result in an altered 
nuclear gene expression profile (Guha and 
Avadhani, 2013; Picard et al., 2014; Guantes 
et al., 2015). 
One of the most well-known genes in 
breast cancer that the extent of its expression 
is used as a prognostic value is ERBB2 
(Harari and Yarden, 2000). ERBB2 as a 
member of Epidermal Growth Factor Recep-
tor family encodes a transmembrane glyco-
protein (HER2) with 185 KDa weight. It has 
a tyrosine kinase activity. It modulates sev-
eral cellular functions by binding to other 
ligand bound EGF receptor which subse-
quently activates downstream signaling cas-
cades including the MAP kinase, phosphati-
dylinositol-3-kinase (PI3-K) and calcium 
signaling pathways (Kauraniemi and 
Kallioniemi, 2006). ERBB2 amplification 
and/or overexpression has been reported in 
15-30 % of human breast cancer malignan-
cies and has been shown to contribute in an 
increased risk of recurrent disease and poor 
clinical outcome by promoting many cellular 
functions including DNA synthesis, cell pro-
liferation, and cell survival. 
The crosstalk between ERBB2 and mito-
chondria has been indicated by different 
studies. Suppressing apoptosis is known as a 
preliminary function of HER2 to enhance 
cell survival (Carpenter and Lo, 2013). 
ERBB2 has a regulatory role over the respira-
tory function of the mitochondria by chang-
ing the oxidative phosphorylation to the aer-
obic glycolysis for cancerous cells as an en-
ergy source. Moreover, it has been indicated 
that ERBB2 induces mitochondrial malfunc-
tions in cardiac myocyte through its translo-
cation to mitochondria and regulating mito-
chondrial respiratory function (Ding et al., 
2012).  
Today, there is not enough evidence sug-
gesting a link between changes in the ERBB2 
copy number and variability in the mito-
chondrial DNA content. Therefore, this 
study aimed to find out the possible associa-
tion between the mtDNA content and the 
ERBB2 gene amplification. 
 
MATERIALS AND METHODS 
Seventy frozen tumor tissues which were 
histologically confirmed as a breast cancer, 
as well as 8 non-cancerous breast tissues, 
were randomly retrieved from Iran National 
tumor bank, Cancer Institute, Imam Kho-
meini Hospital, Tehran, Iran. Clinico-
pathological status of each tumor tissue in-
cluding size, stage, grade, as well as the sta-
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tus of the receptors including estrogen (ER), 
progesterone (PR), human epidermal growth 
factor receptor-2 (HER2/neu) and tumor-
suppressor protein p53 was also recorded for 
further analysis. An informed consent form 
was obtained from all individuals who were 
enrolled in this study. This study was ap-
proved by the ethics committee of Tehran 
University of Medical Sciences, Tehran, 
Iran.  
 
Total DNA extraction 
Total DNA from all breast tissue samples 
was extracted according to the manufacturer 
instruction using QIAamp DNA mini kit 
(Qiagen). The quality of the extracted DNA 
was checked by running all samples on 
1.5 % agarose gel electrophoresis.  
 
Determination of mtDNA content 
Quantitation of the mitochondrial DNA 
copy number relative to the nuclear DNA 
was carried out by using real-time PCR. 
Firstly, primers for mtDNA and beta-globin, 
as a nuclear DNA, were designed using Pri-
mer3. Mitochondrial Primer sequences were 
selected from ND1 region which were as fol-
lowed; mt-ND1-F- 5’-AACATACCCATG-
GCCAACCT-3’, mt-ND1-R-5’-AGCGAA-
GGGTTGTAGTAGCCC-3’ (Product size: 




duct size: 268-bp). Real-time PCR was then 
performed on Rotor gene Q (QIAGEN, 
USA). Each reaction was carried out in trip-
licate and in a total volume of 10 µl contain-
ing 2 µl nuclease free H2O, 1 μl cDNA (3.12 
ng/µl), 5 μl of 2ൈ SYBER Premix Ex Taq II 
(TaKaRa, Japan), and 1 μl of forward and 
reverse primers (5 pmol/µl). The cycling re-
action was initiated with 30 sec at 95 °C as a 
pre-denaturation step and then followed by 
10 sec at 95 °C, 30 sec at 55 °C and 34 sec at 
72 °C. 
In each PCR run, 8 serially diluted DNA 
samples from 50 ng to 0.39 ng were generat-
ed as a standard curve. The following equa-
tion was then used to quantify the mtDNA 
copy number compared to beta-globin: 2 ΔCt 
(ΔCt = Ct β-globin-Ct ND1) (Kim et al., 
2011).  
 
Multiplex Ligation-dependent Probe  
Amplification (MLPA) 
ERBB2 gene amplification status was de-
termined using SALSA MLPA P078-C1 
Breast Tumor probe kit (MRC, Holland). In 
each PCR reaction, three DNA samples from 
normal breast tissues were included. The no-
template tube containing TE buffer (0.1 mM 
EDTA+10 mM Tris-HCl, pH 8.2) was also 
included in each PCR reaction. All the pro-
cedure including denaturation, hybridization, 
ligation, and PCR reactions were conducted 
in a Peqlab thermocycler (Germany). PCR 
products were subsequently separated on an 
ABI3130 capillary sequencer (Applied Bio-
systems, USA) (Ghaffari et al., 2016). 
 
Multiplex Ligation-dependent Probe  
Amplification analysis 
In order to analyse the ERBB2 gene copy 
number variation status GeneMarker ver 1.6 
(softgenetics, USA) was used. As there are 4 
ERBB2 probes included in this kit, the mean 
value was calculated. The mean value below 
0.7 was considered as a lost, while values be-
tween 0.7–1.3 and >1.3 were assigned as 
normal and amplified, respectively (Ding et 
al., 2012; Ghaffari et al., 2016). 
 
Statistical analysis 
A nonparametric test (Mann-Whitney 
test and Kruskal-Wallis test) was used to 
compare the mtDNA content in 2 case and 
control groups and the pathological findings. 
The same test was used to investigate the as-
sociation of mtDNA content with the ERBB2 
amplification and or deletion. Also, likeli-
hood-ratio chi2 was used to evaluate the as-
sociation between ERBB2 (17q) and HER2. 
Two-sided P less than 0.05 was considered 
as statistically significant.  
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Demographic data for clinico-pathological 
features of breast tumors 
All subjects included in this study were 
females with an average age of 49.26 (+ 
13.19). Concerning the clinico-pathological 
features of the tumors 22.85 %, 44.28 % and 
31.42 % belonged to grade I, grade II and 
grade III, respectively. For the tumor stage, 2 
(2.85 %) belonged to stage I, 41 (58.57 %) 
belonged to stage II, 26 (37.14 %) belonged 
to stage III. Concerning the expression of the 
hormone receptors 44 (62.85 %), 36 
(51.42 %) and (21.42 %) were positive for 
ER, PR, and HER2, respectively. Tumor ag-
gressiveness biomarker, p53, was positive 
for 26 (37.14 %) tumor samples (Table 1). 
 
 
Figure 1: Scatter plot analysis illustrating the 
relative mtDNA content of breast tumor samples 
compared to normal breast tissues. The mean 
value of mtDNA content among cases was 1445 
with max. mtDNA content of 24662 and min. of 
125.4. The mean value in control group was 333 
(max.: 424.6 and min.: 250.7). 
 
Determination of the mtDNA Copy Number 
In this study, distribution of the mtDNA 
copy number showed a wide spectrum com-
pared to normal ones. After normalizing mi-
tochondrial DNA content against the nuclear 
DNA content the average copy number of 
the mtDNA in the tumor tissue and the nor-
mal tissue group was 1445 ± 3473 and 333 ± 
58.11, respectively. The difference between 
the mtDNA content of the tumor-tissue and 
the normal tissue group was statistically sig-
nificant (P = 0.044) (Figure 1).  
 
Table 1: Demographic and disease condition da-
ta of 70 breast cancer patients included in this 
study 
Variables Description 
Age (years) mean േ 
SD 
49.26േ 13.19 
Histological grade N (%) 
I 16 (22.85) 
II 31 (44.28) 
III 22 (31.42) 
Not identified 1 (1.42) 
Cancer stage  
I 2 (2.85) 
II 41 (58.57) 
III 26 (37.14) 
Not identified 1 (1.42) 
Tumor size  
≤ 2 4 (5.71) 
2 < 5 47 (67.14) 
≥ 5 18 (25.71) 




Positive 44 (62.85) 
Negative 18 (25.71) 
Not identified 8 (11.42) 
Progesterone receptor  
Positive 36 (51.42) 
Negative 23 (32.85) 
Not identified 11 (15.71) 
Her2-neu  
Positive (3, 4) 15 (21.42) 
Positive (1, 2) 2 (2.85) 
Negative 42 (60) 
Not identified 11 (15.71) 
P53  
Positive 26 (37.14) 
Negative 18 (25.71) 
Not identified 26 (37.14) 
 
Analyzing MLPA results we found 17 
tumor samples with the ERBB2 gene ampli-
fication which accounts for about 24 % of all 
samples. Studying the mtDNA content of the 
tumor samples according to the ERBB2 am-
plification status, a significant association 
was found in the ERBB2 amplified samples 
and a decreased level of the mtDNA content 
(P= 0.01).  
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Interestingly, based on Immunohisto-
chemistry (IHC) test results, 13 out of 17 
samples were determined positive for HER2 
protein expression (Table 2).  
Analyzing the possible factors affecting 
the mtDNA including patient age of onset, 
tumor size, stage, grade, as well as the status 
of the receptors including estrogen (ER), 
progesterone (PR), human epidermal growth 
factor receptor-2 (HER2/neu) and tumor-
suppressor protein p53 no significant associ-
ation was found (Table 3).  
The same result was found while we in-
vestigated the possible correlation between 
mitochondrial DNA content according to the 
ERBB2 status and the clinico-pathological 
features of the tumors (Table 4). 
 
 
Table 2: The association between ERBB2 (17q) and HER2 by likelihood-ratio chi2 (p<0.001) 
ERBB2 (17q) HER2  
Neg Pos Total 
Deletion 1 (2.38) 1 (5.88) 2 (3.39) 
Normal 38 (90.48) 3 (17.65) 41 (69.49) 
Amplification 3 (7.14) 13 (76.47) 16 (27.12) 
Total 42 (100) 17 (100) 59 (100) 
 
 
Table 3: The possible factors affecting mitochondrial DNA content 
Factor Mitochondrial DNA copy number P-value 
Age   
< 40 2666.3 (5681.5) 0.552 > 40 884.9 (1505.8) 
Pathological findings   
Cancer stage   
I 1374.8 (1548.1) 
0.772 II 1418.8 (2532.2) 
III 1550 (4928.6) 
Histological Grade   
I 773 (1322.3) 
0.399 II 1761.4 (4698.1) 
III 1544.9 (2504.9) 
Tumor size   
< 2 791 (687.6) 
0.140 2 < < 5 900.2 (1612.5) 
> 5 3389.3 (6520.4) 
Estrogen receptor   
Positive 1357.1 (3975.8) 0.524 Negative 1289.4 (2097) 
Progesterone receptor   
Positive 1536.4 (4320.4) 0.943 Negative 1117.1 (1924.4) 
Her2/neu   
Positive 1765.1 (4218.5) 0.073 Negative 428.8 (243.4) 
P53   
Positive 1870.4 (5572.1) 0.357 Negative 1098.1 (2128.1) 
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Table 4: Possible factors affecting mitochondrial DNA content according to the ERBB2 status 






Age < 40 359.3 (102.4) 3344.8 (6381.3) 
> 40 404.1 (217.3) 1045.2 (1719.1) 
P-value 0.833 0.380 
Cancer stage I - 1374.8 (1548.1) 
II 343.4 (196.9) 1703.5 (2784.4) 
III 444.3 (175.3) 2102.8 (6021.9) 
P-value 0.177 0.908 
Histological Grade I 233.9 (153.5) 850.1 (1401.6) 
II 422.6 (220.6) 2398.9 (5635.9) 
III 390.3 (108.9) 1884.5 (2773.6) 
P-value 0.397 0.370 
Tumor size < 2 - 791.1 (678.6) 
2< <5 395.2 (195.7) 1161.5 (1940.7) 
> 5 359.1 (172.4) 3822.2 (6887.6) 
P-value 0.881 0.289 
Estrogen receptor Positive 370.5 (178.7) 1647.3 (4495.2) 
Negative 432.1 (230.1) 1718.1 (2484.1) 
P-value 0.587 0.388 
Progesterone receptor Positive 389.9 (202.6) 1758.3 (4698.8) 
Negative 395.9 (200.3) 1718.1 (2484.1) 
P-value 0.828 0.440 
Her2/neu Positive 374.5 (135.3) 1872.1 (4362.9) 
Negative 398.1 (209.8) 528.7 (350.1) 
P-value 0.946 0.490 
P53 Positive 450.1 (255.8) 2377.6 (6474.3) 
Negative 369.1 (197.6) 1366.6 (2448.3) 




This project describes the outcome of the 
study on 70 breast cancer tumor tissues for 
investigating the possible role of ERBB2 in 
regulating the mtDNA copy number varia-
tion. According to our observations, a signif-
icant decrease in the mtDNA content was 
seen in the ERBB2 amplified samples which 
can prove the possible association between 
the ERBB2 gene amplification and mito-
chondrial genetic content. 
Changes in the mitochondrial DNA, in-
cluding alterations in mtDNA content, have 
been indicated throughout cancers and it has 
been denoted to contribute in mitochondrial 
malfunctions and disease (Malik and Czajka, 
2013). Herein, we found that the overall 
mtDNA content of the tumor tissues was 
significantly higher compared to normal 
ones (0.0436). While statistical analysis 
showed a significant increase in mitochon-
drial genetic content among tumor samples 
however a wide variation was seen in this 
group reinforcing instability in the mtDNA 
copy number preservation. Our findings 
were similar to the observations reported for 
other cancers types including brain (Liang 
and Hays, 1996), head and neck (Jiang et al., 
2005), thyroid (Mambo et al., 2005), lung 
(LEE et al., 2005), and esophageal (Tan et 
al., 2006). Although some studies have indi-
cated a significant increase in mtDNA copy 
number in malignant tissues, however, there 
are few reports with opposite results. Yu and 
coworkers have shown a significant reduc-
tion in mtDNA content of 59 breast cancer 
tumor tissues compared to their adjacent 
normal ones (Yu et al., 2007). Also, Fan and 
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coworkers reported a significant decrease in 
102 breast cancer tumor tissues compared to 
their corresponding normal tissues (Fan et 
al., 2009). A similar phenomenon was also 
reported by another researcher in 2006 
(Tseng et al., 2006). The existence of such 
discrepancy shows that regulation of mito-
chondrial DNA copy number is a complex 
process controlled by different factors. Stud-
ies have demonstrated that different loci both 
on the nuclear and mitochondrial genome are 
responsible for maintenance of mitochondri-
al DNA content. Additionally, it has been 
demonstrated that the content of mtDNA is 
influenced by the activation of many signal-
ing pathways (Rohlenova et al., 2016). Con-
stitutive activation of phosphoinositide 3-
kinase/protein kinase B (PI3K/ AKT) 
through ERBB2 amplification/overexpres-
sion has been shown to have effects on mito-
chondrial function (Rohlenova et al., 2016). 
ERBB2 also controls mitochondrial function 
by activating specific Her-2 related signaling 
pathways that subsequent to this process is 
cancer cell survival and proliferation 
(Rohlenova et al., 2016; Victorino et al., 
2016). Subcellular translocation of ERBB2 
to mitochondria (Ding et al., 2012) and to the 
nucleus (Wang and Hung, 2009) of cancer 
cells has recently been characterized by these 
researchers. These findings reinforce the role 
of ERBB2 in regulating mitochondrial func-




Figure 2: Schematic diagram of ERBB2 cellular signaling pathways known to regulate mito-
chondrial function. ERBB2 modulates several cellular functions by binding to other ligand bound 
EGF receptor which subsequently activates downstream signaling cascades including the MAP ki-
nase, phosphatidylinositol-3-kinase (PI3-K) and calcium signaling pathways. It has been demonstrated 
that nuclear ERBB2 in the presence of unknown transcription factors activates the COX-2 gene. 
Translocation of ERBB2 to the mitochondria has also been observed in cancer cells and has been 
linked to decrease in ATP production and increase in cellular glycolysis. 
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Moreover, frequent amplification of 
ERBB2 has been reported in breast cancer 
tumors with high potential for cell prolifera-
tion, cell motility, invasiveness, and distant 
metastases. In addition, enhanced angiogene-
sis and abridged apoptosis in breast tumors 
have been shown to correlate with ERBB2 
gene amplification (Owens et al., 2004; 
Yaziji et al., 2004; Kim et al., 2008; 
Birnbaum et al., 2009; Ross et al., 2009; 
Meinhardt et al., 2015; Chamizo et al., 
2016). Results of our observations proved 
the ERBB2 amplification in breast tumors by 
the appliance of the MLPA technique. The 
rate of 24 % of ERBB2 amplification in this 
study was similar to the range of previous 
reports (20-30 %) (Owens et al., 2004; Yaziji 
et al., 2004; Kim et al., 2008; Birnbaum et 
al., 2009; Ross et al., 2009; Meinhardt et al., 
2015; Chamizo et al., 2016). Interestingly, in 
our study, the mtDNA content in the ERBB2 
amplified samples was significantly de-
creased (P=0.01). Reduction in the mtDNA 
copy number has been reported to correlate 
with the decreased mitochondrial activity. It 
has been demonstrated that reduction in the 
mtDNA copy number under hypoxic condi-
tion causes cells to shift from oxidative 
phosphorylation to glycolysis. A conse-
quence of this process is a significant de-
crease in the Reactive Oxygen Species 
(ROS) production and leading cells to 
achieve immortalization which is known as 
the hallmark of cancer (Lin et al., 2008). A 
drastic decline in the mtDNA content has al-
so been reported to correlate with a reduction 
in the mitochondrial enzymes activity partic-
ipating in energy metabolism (Meierhofer et 
al., 2004). Moreover, about 76 % of our 
samples with ERBB2 gene amplification 
were determined as HER2 positive using 
Immunohistochemistry (IHC) technique. 
Dickinson and coworkers in an experimental 
study demonstrated that “cancer cells failed 
to expand their mtDNA copy number and in-
crease their respiratory capacity, which is 
underpinned by uncoordinated expression of 
the nuclear-encoded mtDNA replication fac-
tors” (Dickinson et al., 2013). It has been 
shown that replication of mtDNA coincides 
with the up-regulated expression of DNA 
polymerase subunit gamma (POLG) replica-
tion factor (Thundathil et al., 2005; Spikings 
et al., 2007) which is indirectly controlled by 
the overexpression of ErbB-2/HER2 (Kim et 
al., 2011; Lu et al., 2011).  
In this study, the possible association of 
the mtDNA content of breast tumor tissues 
with the clinico-pathological features was al-
so investigated; in regard to hormone recep-
tors-ER and PR- even though we did not find 
a relationship between the two factors, how-
ever, the results of other studies were also 
contradictory. While Lin and co-workers 
have indicated higher mtDNA copy number 
in ER+/ PR+ tumors (Lin et al., 2008), other 
studies (Tseng et al., 2006; Yu et al., 2007) 
have specified a higher mtDNA content in 
the ER-negative and PR-negative tumor 
samples. The presence of such controversy 
might be due to different studied subtypes of 
breast cancers or due to different sample size 
or other participating factors in this phenom-
enon that are not yet well characterized. 
Concerning the therapeutic biomarker p53 
although a regulatory role in mitochondrial 
biogenesis has been reported (Achanta et al., 
2005) however, the association between p53 
and changes in the mtDNA content did not 
result in this study. Concerning the stage of 
tumor progression, in a study, a significant 
decline in the mtDNA content of blood sam-
ples of patients with a breast cancer in stage I 
has been observed. They described that de-
pletion of mtDNA in low stages could possi-
bly prevent cancer cells from apoptosis (Fan 
et al., 2009). Yet, in this study, mtDNA con-
tent did not change by the progression of the 
tumors in different stages. In regard to the 
disease age of onset similar to our findings, 
Fan et al. failed to find a link with mtDNA 
content. Knowing this, however, reduced 
mtDNA copy number has been reported in 
patients aged over 50 (Yu et al., 2007).  
Overall, in this study amplification of 
ERBB2 gene was correlated with decreased 
mtDNA content. Since the activation of 
ERBB2 and downstream signaling pathways 
EXCLI Journal 2018;17:149-158 – ISSN 1611-2156 




are involved in both mitochondrial bioener-
getics machinery and programmed cell 
death, therefore our finding gives rise to this 
idea that ERBB2 might mediate its action by 
regulating mitochondrial function through 
changes in mitochondrial genetic content.  
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